Patents Issued in April 8, 2014
  • Polycondensate, composition, treatment process, and preparation process
    Patent number: 8691193
    Abstract: Polycondensate, composition containing it, especially a nail varnish composition, and process for preparation. The polycondensate may be obtained by reacting: a polyol comprising 3 to 6 hydroxyl groups; a saturated or unsaturated non-aromatic monocarboxylic acid; an aromatic monocarboxylic acid containing 7 to 11 carbon atoms; and a saturated or unsaturated, or even aromatic, linear, branched and/or cyclic polycarboxylic acid, comprising at least two carboxylic groups COOH; and/or a cyclic anhydride of such a polycarboxylic acid.
    Type: Grant
    Filed: March 30, 2007
    Date of Patent: April 8, 2014
    Assignee: L'Oreal
    Inventors: Ivan Rodriguez, Roland Ramin, Pascal Giustiniani, Gerard Malle, Philippe Ilekti
  • Methods of producing lignin peroxidase and its use in skin and hair lightening
    Patent number: 8691194
    Abstract: Methods of producing lignin peroxidase are provided. Also provided are methods and cosmetic compositions suitable for skin and hair lightening as well as kits and an article-of manufacturing including active ingredients for skin and hair lightening.
    Type: Grant
    Filed: May 27, 2008
    Date of Patent: April 8, 2014
    Assignee: R.B.T (Rakuto Bio Technologies) Ltd.
    Inventors: Paula Belinky, Haim Lasser, Carlos Dosoretz
  • Peptide having activity of transforming growth factor and production method therefor
    Patent number: 8691195
    Abstract: The present invention relates to a transforming growth factor-beta (TGF-?)-mimicking peptide containing a particular amino acid sequence and a composition for preventing or treating TGF-?-effective disorders or conditions using the same. The peptide of the present invention may be much higher stability than natural-occurring TGF-? and improve drawbacks caused by high molecular weight of natural-occurring TGF-?. The peptide of this invention can be advantageously applied to treatment or improvement of TGF-?-effective disorders or conditions and have excellent efficacies on skin whitening and wrinkle improvement.
    Type: Grant
    Filed: April 14, 2009
    Date of Patent: April 8, 2014
    Assignee: Caregen Co., Ltd.
    Inventors: Young Ji Chung, Young Deug Kim, Eun Mi Kim, Jeong Jin Choi, Jun Young Choi
  • Photoprotective treatment of keratin fibers by application of heat
    Patent number: 8691196
    Abstract: Keratin fibers, in particular human hair and especially artificially dyed human hair, are protected against the action of atmospheric agents and especially against the action of light by application to the keratin fibers/hair of a composition containing at least one protective agent having a log P of less than or equal to 6, followed by the application to the fibers hair of a heating iron at a temperature of greater than or equal to 60° C.
    Type: Grant
    Filed: June 28, 2006
    Date of Patent: April 8, 2014
    Assignee: L'Oreal
    Inventors: Gilles Genain, Boris Lalleman
  • In-shower lotion compositions comprising up to 10% free fatty acids wherein ratio of unsaturated to saturated fatty acids is at least 1:1
    Patent number: 8691197
    Abstract: This invention relates to rinse-off skin conditioning compositions comprising relatively low amounts of oil/emollient and relatively low amounts of aqueous phase stabilizer/structurant. Use of unsaturated fatty acid (or at least minimum amount of unsaturated fatty acid as percentage of total fatty acid) has been found to result in unexpectedly high hydration. In a second embodiment, use of branched fatty acid (at minimum amount branched as percentage of total) also results in superior hydration. Also mixtures of unsaturated and branched fatty acids can be used. In a second embodiment, the invention relates to method of enhancing hydration using compositions as noted.
    Type: Grant
    Filed: September 5, 2007
    Date of Patent: April 8, 2014
    Assignee: Conopco, Inc.
    Inventors: Rajesh Patel, Rosa Mercedes Paredes
  • Environmentally benign plasticizers based on derivatives of acetone
    Patent number: 8691198
    Abstract: Compounds derived from acetone are provided. Particularly, the compounds are derivatives of hydroxyacetone, including dimers of both 1-hydroxyacetone and 1,3-dihydroxyacetone. The hydroxy moieties on the core hydroxyacetone molecule serves as an attachment point for a variety of moieties (e.g., ethers, esters, phosphorous containing, or nitrogen containing) that are selected to provide the compound with a particular property. Applications of the compounds include plasticizers, supersurfactants, and additives for health care products, such as shampoo and perfume.
    Type: Grant
    Filed: June 27, 2011
    Date of Patent: April 8, 2014
    Assignee: Somogyi AgTech LLC
    Inventors: Gregory David Phelan, William Brenden Carlson
  • Ethylenic copolymers, compositions and methods of the same
    Patent number: 8691199
    Abstract: The present disclosure relates to novel ethylenic copolymers comprising from 10% to 80% by weight, of at least one monomer of polyethylene glycol (meth)acrylate type, from 20% to 90% by weight, of at least one anionic monomer, and from 0% to 70% by weight, at least one additional nonionic hydrophilic monomer. The disclosure also relates to a composition, such as cosmetic or pharmaceutical compositions, comprising the copolymers and to a method of using the same.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: April 8, 2014
    Assignee: L'Oreal
    Inventors: Nathalie Mougin, Gwenaelle Jegou
  • Pump-dispenser bottle device containing a polycondensate comprising at least one polyurethane and/or polyurea unit
    Patent number: 8691200
    Abstract: The invention concerns aerosol devices comprising a reservoir containing, in a cosmetically suitable medium, a multiple-block polymer (A) comprising at least a polyurethane and/or polyurea unit and a film-forming polymer (B), the polymers (A) and (B) and the device being selected so as to obtain, at the device outlet, droplets of composition with average diameter less than 80 ?m. The invention also concerns a hairstyling or hair-fixing method comprising the use of said devices and their use for making a hairstyling product.
    Type: Grant
    Filed: December 8, 2009
    Date of Patent: April 8, 2014
    Assignee: L'Oreal
    Inventor: Arnaud Vilbert
  • Deodorant material
    Patent number: 8691201
    Abstract: An object of the present invention is to provide a deodorant material having an excellent capability of removing an odor, especially a distinctive body odor of the middle-aged and elderly. The deodorant material comprises a polyurethane resin capable of removing the odor of nonenal, preferably further capable of removing the odor of at least one selected from the group consisting of ammonia, acetic acid, and isovaleric acid.
    Type: Grant
    Filed: February 13, 2009
    Date of Patent: April 8, 2014
    Assignee: Toray Opelontex Co., Ltd.
    Inventors: Toshihiro Tanaka, Hirokuni Inoue, Hironori Ishiwata
  • Skin compositions and methods of use thereof
    Patent number: 8691202
    Abstract: Provided are body corrective cosmetic formulations and methods of use thereof.
    Type: Grant
    Filed: August 20, 2013
    Date of Patent: April 8, 2014
    Assignee: Living Proof, Inc.
    Inventors: Betty Yu, Joseph Lomakin, Soo-Young Kang, Benjamin W. Adams
  • Method comprising contacting tissue with a cross-linkable polyester prepolymer
    Patent number: 8691203
    Abstract: The present inventions in various aspects provide elastic biodegradable polymers. In various embodiments, the polymers are formed by the reaction of a multifunctional alcohol or ether and a difunctional or higher order acid to form a pre-polymer, which is cross-linked to form the elastic biodegradable polymer. In preferred embodiments, the cross-linking is performed by functionalization of one or more OR groups on the pre-polymer backbone with vinyl, followed by photopolymerization to form the elastic biodegradable polymer composition or material. Preferably, acrylate is used to add one or more vinyls to the backbone of the pre-polymer to form an acrylated pre-polymer. In various embodiments, acrylated pre-polymers are co-polymerized with one or more acrylated co-polymers.
    Type: Grant
    Filed: March 23, 2012
    Date of Patent: April 8, 2014
    Assignee: Massachusetts Institute of Technology
    Inventors: Christopher J. Bettinger, Joost P. Bruggeman, Lino Da Silva Ferreira, Jeffrey M. Karp, Robert S. Langer, Christiaan Nijst, Andreas Zumbuehl, Jason Burdick, Sonia J. Kim
  • Synthetic diblock copolypeptide hydrogels for use in the central nervous system
    Patent number: 8691204
    Abstract: This invention relates, e.g., to a composition suitable for administration to the central nervous system (CNS), comprising a block copolypeptide hydrogel, which comprises a biologically active material that is mixed with the hydrogel or that is attached to the polypeptide chain of the hydrogel, wherein the composition is suitable for administration to the CNS. Also disclosed are methods of making and using compositions of the invention as depots or as scaffolds for cell migration, and pharmaceutical compositions and kits for implementing methods of the invention.
    Type: Grant
    Filed: February 18, 2010
    Date of Patent: April 8, 2014
    Assignee: The Regents of the University of California
    Inventors: Timothy J. Deming, Michael V. Sofroniew, Chu-Ya Yang, BingBing Song, Yan Ao
  • Mono- and di-PEG IL-10 production; and uses
    Patent number: 8691205
    Abstract: Provided are methods of producing a mixture of mono- and di-pegylated IL-10.
    Type: Grant
    Filed: December 15, 2009
    Date of Patent: April 8, 2014
    Assignee: Merck Sharp & Dohme Corporation
    Inventors: Steven J. Blaisdell, Collette M. Cutler, Brittany C. Paporello, Alexandre Ambrogelly
  • Formation of hydrogel in the presence of peroxidase and low concentration of hydrogen peroxide
    Patent number: 8691206
    Abstract: In a process of forming a hydrogel from a mixture comprising hydrogen peroxide (H2O2), horseradish peroxidase (HRP), and a polymer comprising a crosslinkable phenol group, the gelation rate in the solution and the crosslinking density in the hydrogel can be independently adjusted or controlled by selection of the molarity of H2O2 and concentration of HRP in the solution when the molarity of H2O2 is limited to be within a range and the concentration of HRP is limited to be above a threshold. A method for determining the range and threshold is disclosed. The hydrogel may be used to grow cells, in which case, the molarity of H2O2 may be selected to affect the differentiation or growth rate of the cells in the hydrogel. Also, the hydrogel system may be used for sustained delivery of a therapeutic protein, for example in the treatment of liver cancer, fibrosis or hepatitis.
    Type: Grant
    Filed: December 23, 2011
    Date of Patent: April 8, 2014
    Assignee: Agency for Science, Technology and Research
    Inventors: Motoichi Kurisawa, Li Shan Wang, Joo Eun Chung, Fan Lee, Keming Xu, Hirohisa Yano
  • Transplantation of cells expressing markers for photoreceptor cells and retinal ganglion cells induced from Müller stem cells
    Patent number: 8691207
    Abstract: A method for the production of retinal cells, useful in transplantation therapy, comprises: (i) obtaining one or more mammalian adult Müller cells; and (ii) culturing the cells in the presence of an extracellular matrix protein and a growth factor to thereby induce dedifferentiation of the Müller cells into a progenitor phenotype.
    Type: Grant
    Filed: December 30, 2011
    Date of Patent: April 8, 2014
    Assignee: The Institute of Ophthalmology
    Inventors: Gloria Astrid Limb, Peng Tee Khaw
  • Compositions and methods for treating hypophosphatasia
    Patent number: 8691208
    Abstract: The present invention provides compositions and methods for use in enzyme replacement therapy. The inventors disclose a method of producing membrane bound enzymes in an active soluble form by eliminating the glycosylphosphatidylinositol (GPI) membrane anchor. In particular the inventors disclose a soluble active form of the membrane bound enzyme TNSALP which they produced by deleting the GPI anchor single peptide sequence. They have further shown that this composition is useful for treatment of hypophosphatasia. The inventors also disclose oligo acid amino acid variants thereof which specifically target bone tissue.
    Type: Grant
    Filed: March 24, 2011
    Date of Patent: April 8, 2014
    Assignees: Saint Louis University, Shimane University, Kanazawa University
    Inventors: Shunji Tomatsu, William Sly, Jeffrey Grubb, Tatsuo Nishioka, Ken-ichi Miyamoto, Seiji Yamaguchi
  • Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
    Patent number: 8691209
    Abstract: The invention relates to the finding that virus like particles (VLPs) can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs). Such CpG-VLPs are dramatically more immunogenic than their CpG-free counterparts and induce enhanced B and T cell responses. The immune response against antigens optionally coupled, fused or attached otherwise to the VLPs is similarly enhanced as the immune response against the VLP itself. In addition, the T cell responses against both the VLPs and antigens are especially directed to the Th1 type. Antigens attached to CpG-loaded VLPs may therefore be ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases.
    Type: Grant
    Filed: November 10, 2011
    Date of Patent: April 8, 2014
    Assignee: Cytos Biotechnology AG
    Inventors: Martin F. Bachmann, Tazio Storni, Patrik Maurer, Alain Tissot, Katrin Schwarz, Edwin Meijerink, Gerd Lipowsky, Paul Pumpens, Indulis Cielens, Regina Renhofa
  • Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptors and adaptors thereof
    Patent number: 8691210
    Abstract: Provided are methods for activating an antigen-presenting cell and eliciting an immune response by inducing pattern recognition receptor activity, and CD40 activity. Also provided are methods for activating an antigen-presenting cell and eliciting an immune response by inducing CD40 activity without prostaglandin E2. Also provided are methods for activating an antigen-presenting cell and eliciting an immune response by inducing an inducible chimeric molecule comprising a region of a pattern recognition receptor or an adaptor thereof.
    Type: Grant
    Filed: October 19, 2007
    Date of Patent: April 8, 2014
    Inventors: David M Spencer, Natalia Lapteva
  • Suppression of immune response to factor VIII in hemophilia A patients
    Patent number: 8691211
    Abstract: This invention relates to methods and compositions for suppressing an immune response to Factor VIII in subjects suffering from hemophilia A and having preformed inhibitor antibodies against Factor VIII, and compositions and methods that advantageously render subjects amenable to standard treatments for hemophilia A, including Factor VIII replacement therapy.
    Type: Grant
    Filed: March 10, 2010
    Date of Patent: April 8, 2014
    Assignee: Puget Sound Blood Center
    Inventor: Neil Cary Josephson
  • Therapeutic/prophylactic agent for prostate cancer
    Patent number: 8691212
    Abstract: Provided are a novel therapeutic agent and therapeutic method for prostatic cancers. More specifically, a prostatic cancer therapeutic/prophylactic agent having a viral envelope vector, particularly a Sendai viral envelope vector, as an active ingredient, the therapeutic/prophylactic agent which is an apoptosis induction promoter, the therapeutic/prophylactic agent used for prostatic cancers whose androgen susceptibility has been partially or completely reduced, and a melanoma therapeutic/prophylactic agent containing a Sendai viral envelope vector as the only active ingredient, and the like are provided.
    Type: Grant
    Filed: September 16, 2009
    Date of Patent: April 8, 2014
    Assignee: Genomldea Inc.
    Inventors: Yasufumi Kaneda, Yoshifumi Kawaguchi, Toshimitsu Itai
  • Protein free formula
    Patent number: 8691213
    Abstract: The invention relates to the use of composition comprising free amino acids as a sole source of protein, a fatty acid source comprising long chain polyunsaturated fatty acids, a carbohydrate source comprising digestible and indigestible carbohydrates, and milk protein free Bifidobacteria for treating a person suffering from (a) colic, congestion, runny nose, wheezing, vomiting, diarrhea, bloody stools, mucus in stools, rash, eczema, gastroesophageal reflux, eosinophilic esophagitis or asthma; (b) cow's milk allergy and/or food protein intolerance; and/or (c) infections, wherein the indigestible carbohydrate is selected from a milk protein free source and the total composition is essentially free of intact proteins.
    Type: Grant
    Filed: July 5, 2007
    Date of Patent: April 8, 2014
    Assignee: SHS International
    Inventors: Jane Elizabeth Langford, Ian Sullivan, Catherine Teresa Deering, Sandra Helen Giffen
  • Use of for treatment of virus infections
    Patent number: 8691214
    Abstract: The present invention relates to the use of at least one strain of probiotic bacteria selected from Lactobacillus for the manufacture of a pharmaceutical composition for the treatment and/or prevention of a virus infection.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: April 8, 2014
    Assignee: Probi AB
    Inventors: Jan Alenfall, Anna Berggren, Carola Rask, Agnes Wold
  • Anti-viral protection with viruses containing defective genome segments
    Patent number: 8691215
    Abstract: The invention relates to virology and the prevention and/or treatment of viral infection and disease in animals, including birds and humans. The invention relates to the field of antiviral treatments. The invention further relates to methods of stimulating innate immunity and natural interferon production in humans or animals and in component parts of humans or animals, including cells and tissues. The invention also relates to the field of defective interfering (DI) viruses, including cloned DI viruses.
    Type: Grant
    Filed: December 8, 2009
    Date of Patent: April 8, 2014
    Assignee: The University of Warwick
    Inventors: Nigel Dimmock, Andrew Easton
  • Methods of using regenerative cells to promote wound healing
    Patent number: 8691216
    Abstract: Cells present in adipose tissue are used to promote wound healing in a patient. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the regenerative cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic benefit.
    Type: Grant
    Filed: January 27, 2012
    Date of Patent: April 8, 2014
    Assignee: Cytori Therapeutics, Inc.
    Inventors: John K. Fraser, Marc H. Hedrick, Eric Daniels
  • Placental stem cell populations
    Patent number: 8691217
    Abstract: The present invention provides placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. The invention also provides methods of differentiating the placental stem cells. The invention further provides methods of using the placental stem cells in assays and for transplanting.
    Type: Grant
    Filed: May 24, 2012
    Date of Patent: April 8, 2014
    Assignee: Anthrogenesis Corporation
    Inventors: James Edinger, Qian Ye, Jai-Lun Wang, Robert J. Hariri
  • Vermin extermination using lysozyme, salt or biological fragment thereof, or lysozyme-related peptide as an egg recognition pheromone
    Patent number: 8691218
    Abstract: The present invention provides a mimetic egg comprising lysozyme, a salt or biological fragment thereof or a lysozyme-related peptide and an active ingredient in its base material mimicking an egg of a vermin; and a vermin exterminating method using the mimetic egg.
    Type: Grant
    Filed: February 15, 2008
    Date of Patent: April 8, 2014
    Assignee: National University Corporation Okayama University
    Inventors: Kenji Matsuura, Takashi Tamura, Norimasa Kobayashi
  • sp. nov. and use for control of insect pests
    Patent number: 8691219
    Abstract: Chromobacterium subtsugae sp. nov., a new species of the genus Chromobacterium which possesses insecticidal activity, is described. The invention also relates to insecticidally-active metabolites obtained from the strain and to insecticidal compositions comprising cultures of the strain and/or supernatants, filtrates, and extracts obtained from the strain, and use thereof to control insect pests.
    Type: Grant
    Filed: February 8, 2007
    Date of Patent: April 8, 2014
    Assignee: The United States of America as represented by the Secretary of Agriculture
    Inventors: Phyllis A. W. Martin, Ashaki D. S. Shropshire, Dawn E. Gundersen-Rindal, Michael B. Blackburn
  • Powdery malted rice extract composition
    Patent number: 8691220
    Abstract: Disclosed are an agent for promoting proliferation of lactic acid bacteria, a preservative, and others, all of which do not deteriorate the flavor of food products. Specifically disclosed is a powdery malted rice extract composition obtained by inoculating lactic acid bacteria in a liquid prepared from a water extract of malted rice so that its Brix degree is 0.01 to 10, culturing the bacteria in the liquid, followed by drying the resulting culture.
    Type: Grant
    Filed: October 25, 2010
    Date of Patent: April 8, 2014
    Assignee: Hiroshima University
    Inventor: Masanori Sugiyama
  • Analgesic treatment with prolonged effect
    Patent number: 8691221
    Abstract: Use of an anti-TrkA antibody capable of inhibiting the binding between NGF and TrkA, in particular capable of blocking the biological activity of TrkA, for the preparation of a medicament for treating and/or preventing chronic pain.
    Type: Grant
    Filed: June 7, 2006
    Date of Patent: April 8, 2014
    Assignee: Lay Line Genomics S.p.A.
    Inventors: Flaminia Pavone, Sara Marinelli, Antonio Cattaneo, Gabriele Ugolini
  • NLRR-1 antagonists and uses thereof
    Patent number: 8691222
    Abstract: NLRR-1 antagonists and methods of their use in treating cancer and other disorders are provided.
    Type: Grant
    Filed: October 1, 2008
    Date of Patent: April 8, 2014
    Assignee: Genentech, Inc.
    Inventors: Meredith Hazen, Jo-Anne S. Hongo, Victoria Smith, Susanna Stinson
  • Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof
    Patent number: 8691223
    Abstract: Described are binding molecules such as human monoclonal antibodies that bind to influenza virus H5N1 and have neutralizing activity against influenza virus H5N1. Also described are nucleic acid molecules encoding the antibodies, and compositions comprising the antibodies and methods of identifying or producing the antibodies. The antibodies can be used in the diagnosis, prophylaxis, and/or treatment of an influenza virus H5N1 infection. In certain embodiments, the antibodies provide cross-subtype protection in vivo, such that infections with H5, H2, H6, H9, and H1-based influenza subtypes can be prevented and/or treated.
    Type: Grant
    Filed: December 9, 2011
    Date of Patent: April 8, 2014
    Assignee: Crucell Holland B.V.
    Inventors: Edward Norbert Van Den Brink, Cornelis Adriaan De Kruif, Mark Throsby
  • Anti-A? globulomer 5F7 antibodies
    Patent number: 8691224
    Abstract: Anti-A? globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies. The present invention relates to anti-A? globulomer antibodies having a binding affinity to A?(20-42) globulomer that is greater than the binding affinity of the antibody to A?(1-42) globulomer, antigen-binding moieties thereof, hybridomas producing said antibodies, nucleic acids encoding said antibodies, vectors comprising said nucleic acids, host cells comprising said vectors, methods of producing said antibodies, compositions comprising said antibodies, therapeutic and diagnostic uses of said antibodies and corresponding methods relating to Alzheimer's disease and other amyloidoses.
    Type: Grant
    Filed: November 30, 2006
    Date of Patent: April 8, 2014
    Assignees: AbbVie Inc., AbbVie Deutschland GmbH & Co. KG
    Inventors: Stefan Barghorn, Heinz Hillen, Boris Labkovsky, Andreas R. Striebinger, Patrick Keller, Ulrich Ebert
  • Antibodies against the ectodomain of ErbB3 and uses thereof
    Patent number: 8691225
    Abstract: The present invention provides a novel class of antibodies and antigen binding fragments thereof that bind the extracellular domain of ErbB3 receptor and inhibit various ErbB3 functions. For example, the antibodies and antigen binding fragments described herein are capable of binding to the receptor designated ErbB3 and inhibiting EGF-like ligand mediated phosphorylation of the receptor. Such antibodies and antigen binding fragments thereof have the useful characteristic of inhibiting the proliferation of cancer cells expressing ErbB3.
    Type: Grant
    Filed: August 21, 2009
    Date of Patent: April 8, 2014
    Assignee: Merrimack Pharmaceuticals, Inc.
    Inventors: Birgit Schoeberl, Ulrik Nielsen, Michael Feldhaus, Arumugam Muruganandam, David Buckler
  • Humanized anti-human tumor necrosis factor alpha monoclonal antibody and sequence thereof
    Patent number: 8691226
    Abstract: An amino acid sequence of a humanized monoclonal antibody includes an amino acid sequence of a light chain variable region, which includes SEQ ID. NO.: 1; and an amino acid sequence of a heavy chain variable region, which comprises SEQ ID. NO.: 2, wherein SEQ ID. NO.: 1 and SEQ ID. NO.: 2 have at least one amino acid substitution which is selected from a group consisting of isoleucine at position 10 of SEQ ID. NO.: 1, being substituted with threonine, lysine at position 18 of SEQ ID. NO.: 1, being substituted with arginine, lysine at position 2 of SEQ ID. NO.: 2, being substituted with glutamine, tryptophan at position 10 of SEQ ID. NO.: 2, being substituted with leucine, lysine at position 18 of SEQ ID. NO.: 2, being substituted with arginine and glutamic acid at position 41 of SEQ ID. NO.: 2, being substituted with glycine.
    Type: Grant
    Filed: December 27, 2010
    Date of Patent: April 8, 2014
    Assignee: Industrial Technology Research Institute
    Inventors: Wei-Chun Chiu, Min-Yuan Chou
  • Methods of treating multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease using agonists antibodies to PILR-?
    Patent number: 8691227
    Abstract: The present invention provides methods of using PILR? agonists, or PILR? antagonists, to treat immune disorders, such as autoimmune and inflammatory disorders, including CNS, joint and gut inflammation.
    Type: Grant
    Filed: December 10, 2010
    Date of Patent: April 8, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Cristina M. Tato, Barbara Joyce-Shaikh, Daniel J. Cua
  • Stable and soluble antibodies inhibiting TNF?
    Patent number: 8691228
    Abstract: The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNF?, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF?, and low immunogenicity. Said antibodies are designed for the diagnosis and/or treatment of TNF?-related disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.
    Type: Grant
    Filed: December 7, 2012
    Date of Patent: April 8, 2014
    Assignee: ESBATech, an Alcon Biomedical Research Unit LLC
    Inventors: Stefan Ewert, Alcide Barberis, David Urech, Adrian Auf Der Maur, Peter Lichtlen
  • Method of PLSCR inhibition for cancer therapy
    Patent number: 8691229
    Abstract: The present invention relates to a method of using inhibitors of phospholipid scramblases (PLSCRs) for the prophylactic or therapeutic treatment of cancers. The PLSCR-inhibitors of the invention comprise compounds PLSCR-specific monoclonal antibodies, antagonists or nucleic acids, which have ability to decrease the level and/or biological activity of PLSCRs in cancer cells.
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: April 8, 2014
    Assignee: Err-Cheng CHAN
    Inventors: Err-Cheng Chan, Hong-Arh Fan, Kuei-Tien Chen, Yung-Bin Kuo, Jinn-Shiun Chen, Chung-Wei Fan
  • Methods for inhibiting hematopoiesis with a hedgehog antagonist
    Patent number: 8691230
    Abstract: This application pertains to methods and compositions that modulate proliferation and/or differentiation of undifferentiated mesodermally-derived cells so as to have an effect on at least one of vascular growth and hematopoiesis.
    Type: Grant
    Filed: June 27, 2012
    Date of Patent: April 8, 2014
    Assignee: The President and Fellows of Harvard College
    Inventors: Margaret H. Baron, Sarah M. Farrington, Maria Belaoussoff
  • Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
    Patent number: 8691231
    Abstract: Disclosed are pharmaceutical preparations for, and methods for determining, appropriate and effective treatment with therapeutic agents comprising a single species of anti-EGFR monoclonal antibody or therapeutic agents comprising a plurality of species of such antibodies, as well as kits useful for making such determinations.
    Type: Grant
    Filed: June 4, 2012
    Date of Patent: April 8, 2014
    Assignee: Merrimack Pharmaceuticals, Inc.
    Inventors: Raghida Bukhalid, Ulrik Nielsen, Shannon Werner, Jeffrey David Kearns
  • Extending time to disease progression or survival in cancer patients
    Patent number: 8691232
    Abstract: The present application describes extending time to disease progression or survival in a cancer patient, where the patient's cancer displays HER activation, by treating the patient with a HER dimerization inhibitor, such as pertuzumab.
    Type: Grant
    Filed: January 21, 2011
    Date of Patent: April 8, 2014
    Assignee: Genentech, Inc.
    Inventors: Mika K. Derynck, Stephen M. Kelsey
  • Antibody molecules having binding specificity for human IL-13
    Patent number: 8691233
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human IL-13, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Grant
    Filed: March 10, 2010
    Date of Patent: April 8, 2014
    Assignee: UCB Pharma S.A.
    Inventors: Neil Gozzard, Alastair David Griffiths Lawson, Daniel John Lightwood, Roger Thomas Palframan, Bryan John Smith, Kerry Louise Tyson
  • Vaccine formulation potentiated by the combination of DNA and an antigen
    Patent number: 8691234
    Abstract: Formulation of vaccine antigens, containing as main components: a—) one or several DNA expressing one or several proteins in the immunized individuals and b—) a viral antigen, in appropriate proportions. Development of new formulations, minimizing the number of components that enhance and diversify the spectrum of immune response against different pathogenic entities and generating combined vaccines against pathogens. These formulations can be applied in the pharmaceutical industry for preventive and-or therapeutic use in human.
    Type: Grant
    Filed: April 27, 2009
    Date of Patent: April 8, 2014
    Assignee: Centro de Ingenieria Genetica y Biotecnologia
    Inventors: Santiago Duenas Carrera, Juan Morales Grillo, Liz Alvarez-Lajonchere Ponce de Leon, Alexis Musacchio Lasa, Rolando Pajon Feyt, Ariel Vina Rodriguez, Julio C. Alvarez Obregon, Nelson Acosta Rivero, Gillian Martinez Donato
  • Absorbable crystalline polyether-ester-urethane-based bioactive luminal liner compositions
    Patent number: 8691235
    Abstract: Bioactive hydroforming luminal liner compositions are formed of an absorbable crystalline amphiphilic polyether-ester-urethane dissolved in a liquid derivative of a polyether glycol that undergoes transformation into a tissue-adhering, resilient interior cover or liner for the controlled release of its bioactive payload at clinically compromised conduits in humans as in the case of bacteria- and yeast-infected vaginal canals, esophagi, and arteries following angioplasty.
    Type: Grant
    Filed: April 5, 2010
    Date of Patent: April 8, 2014
    Assignee: Poly-Med, Inc.
    Inventors: Shalaby W Shalaby, David Ingram, Georgios T Hilas, Sheila Nagatomi
  • Vaccine for a therapeutic or a prophylactic treatment of myasthenia gravis
    Patent number: 8691236
    Abstract: Complementary peptide having at least a sequence complementary to a major immunogenic region of an acetylcholine receptor involved in myasthenia gravis, characterized in that the complementary peptide has at least a sequence SEQ. ID. NO1 with a tryptophan in position 8, carrying at least one optionally substituted hydrocarbon group. Therapeutic composition comprising the Complementary peptide according to the invention and use thereof for manufacturing a vaccine to be used in a therapeutic or prophylactic treatment of myasthenia gravis in mammals.
    Type: Grant
    Filed: March 23, 2006
    Date of Patent: April 8, 2014
    Assignee: Cura Vac, Inc.
    Inventors: J. Edwin Blalock, Stephane P. Huberty
  • proteins and methods of use thereof
    Patent number: 8691237
    Abstract: Compositions and methods for the diagnosis and prevention of B. abortus infection are provided.
    Type: Grant
    Filed: December 3, 2010
    Date of Patent: April 8, 2014
    Assignee: The University of Wyoming
    Inventors: Gerard P. Andrews, John E. Lowry
  • High growth reassortant influenza A virus
    Patent number: 8691238
    Abstract: The present invention provides a high growth reassortant influenza A virus having at least two gene segments of seasonal or pandemic strain origin, a PB1 gene segment of A/Texas/1/77 strain origin and a PA gene segment of A/Puerto Rico/8/34 (H1N1) origin coding for a PA protein comprising at least one amino acid modification at any one of positions 10, 275, 682, according to SEQ ID No. 1. Further provided are vaccine formulations comprising the reassortant influenza A virus of the invention.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: April 8, 2014
    Assignee: Baxter Healthcare SA
    Inventors: Thomas Muster, Markus Wolschek, Andrej Egorov, Elisabeth Roethl, Julia Romanova, Michael Bergmann
  • Influenza hemagglutinin and neuraminidase variants
    Patent number: 8691239
    Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.
    Type: Grant
    Filed: September 25, 2013
    Date of Patent: April 8, 2014
    Assignee: MedImmune, LLC
    Inventors: Chin-Fen Yang, George Kemble, Chongguang Liu
  • Reoviruses having modified sequences
    Patent number: 8691241
    Abstract: The invention provides for modified reovirus nucleic acid sequences and modified reovirus polypeptide sequences as well as reoviruses containing such modified nucleic acid or polypeptide sequences. The invention also provides for pharmaceutical compositions that include reoviruses having a modified sequence as well as methods of making and using such reoviruses.
    Type: Grant
    Filed: August 2, 2010
    Date of Patent: April 8, 2014
    Assignee: Oncolytics Biotech Inc.
    Inventor: Matthew C Coffey
  • DIV1B for use as vaccine
    Patent number: 8691242
    Abstract: The invention relates to an antigenic polypeptide referred to as DivlB and variants thereof, vaccines comprising said polypeptide and the use of the vaccine in protecting subjects from microbial infection.
    Type: Grant
    Filed: September 13, 2010
    Date of Patent: April 8, 2014
    Assignee: Absynth Biologics Limited
    Inventors: Jorge Garcia Lara, Simon Foster
  • Protein-based vaccine
    Patent number: 8691243
    Abstract: Vaccine compositions and methods for protecting a mammalian subject against infection with S. pneumoniae are disclosed. The vaccines and methods comprise an effective amount of one or more Streptococcus pneumoniae cell wall and/or cell membrane proteins and/or immunogenically-active fragments, derivatives or modifications thereof, wherein the proteins are selected from a defined group of proteins associated with age-dependent immunological responses.
    Type: Grant
    Filed: January 4, 2013
    Date of Patent: April 8, 2014
    Assignee: Ben-Gurion University of the Negev Research and Development Authority
    Inventor: Yaffa Mizrachi Nebenzahl